Zhejiang Ausun Pharmaceutical (SHA:603229) received a certificate of suitability for its pilocarpine hydrochloride active pharmaceutical ingredient from the European Directorate for the Quality of Medicines and Healthcare.
Pilocarpine Hydrochloride, initially used for dry mouth, is used to treat glaucoma and ocular hypertension, according to a Friday filing with the Shanghai bourse.
The approval enables the sale of the API in the European market, the pharmaceutical company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.